People · Operator
Named in public records as an officer, director or promoter · active 2015–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AveXis, Inc. | — | Biotechnology | Series C | $65.0M | $2.7B | 2015 |
Bong D. Koh at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bong D. Koh on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sean Nolan | 1 | 3 |
| John D. Harkey | 1 | 3 |
| James F. L'Italien | 1 | 1 |
| Andrew F. Knudten | 1 | 1 |
| Paul D. Manning | 1 | 1 |
| Sukumar F. Nagendran | 1 | 1 |
| Thomas D. Dee | 1 | 1 |
| Carole D. Nuechterlain | 1 | 1 |
| Brian D. Kaspar | 1 | 1 |
| Jonathan D. Leff | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.